Abbott Laboratories (ABT) stock declined sharply in pre-market trading despite solid first-quarter revenue growth and stable earnings performance. The drop followed reduced full-year guidance and weakening operating margins, which signaled pressure on profitability. The market reacted negatively, pushing shares to $97.10, down 4.34%, after a steep sell-off.
Abbott Laboratories reported first-quarter revenue of $11.16 billion, exceeding analyst estimates by 1.3%. Revenue grew 7.8% year over year, reflecting steady demand across its healthcare segments.Comparable growth remained moderate, which suggests underlying expansion stayed controlled.
The company delivered adjusted earnings per share of $1.15, matching consensus expectations without surprises.Earnings increased from $1.09 in the same period last year, indicating moderate profitability improvement. Still, the flat alignment with estimates limited any positive market reaction.
Abbott maintained a broad product portfolio across diagnostics, devices, nutrition, and branded pharmaceuticals.Recent innovation and expansion efforts supported steady top-line growth over recent quarters.Long-term revenue growth averaged only 3.9% annually, which remains below stronger healthcare peers.
Abbott reported an adjusted operating margin of 12%, down sharply from 16.3% in the prior year.Rising expenses outpaced revenue growth, which weakened operational efficiency during the quarter. This contraction raised concerns about cost control and scaling effectiveness.
The company also reduced its full-year adjusted EPS guidance to a midpoint of $5.48. This revision marked a 3.4% decline from earlier expectations, which signaled cautious internal projections.The lowered outlook contributed significantly to the negative stock reaction.
Over the past five years, Abbott’s operating margin declined by 6.2 percentage points, reflecting sustained profitability pressure. Earnings per share grew only 3.8% annually, aligning with modest revenue expansion trends. This combination highlighted limited margin leverage despite business scale.
Abbott completed its acquisition of Exact Sciences, strengthening its position in oncology diagnostics. This move introduced a new high-growth segment to support future revenue acceleration. The acquisition also added near-term earnings dilution, which influenced updated guidance.
The company continued advancing medical innovation through collaborations and clinical developments across cardiovascular and diabetes care. New product studies showed improved outcomes, supporting long-term healthcare relevance and demand. These developments positioned Abbott for gradual growth improvement.
Analysts expect Abbott’s revenue to grow 11.1% over the next 12 months, indicating stronger forward momentum. Projected EPS growth of 8.5% reflects anticipated recovery in profitability metrics.Near-term margin pressure and guidance cuts continue to weigh on sentiment.
The post Abbott Laboratories (ABT) Stock: Declines Despite 7.8% Revenue Growth and Strategic Expansion in Q1 appeared first on CoinCentral.
